 | • レポートコード：GIR-2104Z10300 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、経口血糖降下薬・インスリン類似体のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。経口血糖降下薬・インスリン類似体の種類別市場規模（インスリン分泌促進物質、α-グルコシダーゼ阻害剤、インスリン増感剤）、用途別市場規模（病院、ドラッグストア、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・経口血糖降下薬・インスリン類似体の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Sanofi-Aventis、Ganlee、Biocon、Novo Nordisk、Eli Lilly、Tonghua Dongbao、United Laboratory、Jiangsu Wanbang ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：インスリン分泌促進物質、α-グルコシダーゼ阻害剤、インスリン増感剤 ・用途別分析2016年-2026年：病院、ドラッグストア、その他 ・経口血糖降下薬・インスリン類似体の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・経口血糖降下薬・インスリン類似体のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・経口血糖降下薬・インスリン類似体のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・経口血糖降下薬・インスリン類似体の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・経口血糖降下薬・インスリン類似体の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Oral Hypoglycemic Agents and Insulin Analogues market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Oral Hypoglycemic Agents and Insulin Analogues size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Oral Hypoglycemic Agents and Insulin Analogues market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Oral Hypoglycemic Agents and Insulin Analogues market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Insulin Secretagogues
Alpha-glucosidase Inhibitors
Insulin Sensitizers
Market segment by Application can be divided into
Hospitals
Drug Store
Others
The key market players for global Oral Hypoglycemic Agents and Insulin Analogues market are listed below:
Sanofi-Aventis
Ganlee
Biocon
Novo Nordisk
Eli Lilly
Tonghua Dongbao
United Laboratory
Jiangsu Wanbang
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Oral Hypoglycemic Agents and Insulin Analogues Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Insulin Secretagogues
1.2.3 Alpha-glucosidase Inhibitors
1.2.4 Insulin Sensitizers
1.3 Market Analysis by Application
1.3.1 Overview: Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Drug Store
1.3.4 Others
1.4 Global Oral Hypoglycemic Agents and Insulin Analogues Market Size & Forecast
1.4.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales in Value (2016-2026))
1.4.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume (2016-2026)
1.4.3 Global Oral Hypoglycemic Agents and Insulin Analogues Price by Type (2016-2026) & (USD/MT)
1.5 Global Oral Hypoglycemic Agents and Insulin Analogues Production Capacity Analysis
1.5.1 Global Oral Hypoglycemic Agents and Insulin Analogues Total Production Capacity (2016-2026)
1.5.2 Global Oral Hypoglycemic Agents and Insulin Analogues Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Oral Hypoglycemic Agents and Insulin Analogues Market Drivers
1.6.2 Oral Hypoglycemic Agents and Insulin Analogues Market Restraints
1.6.3 Oral Hypoglycemic Agents and Insulin Analogues Trends Analysis
2 Manufacturers Profiles
2.1 Sanofi-Aventis
2.1.1 Sanofi-Aventis Details
2.1.2 Sanofi-Aventis Major Business
2.1.3 Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Product and Services
2.1.4 Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Ganlee
2.2.1 Ganlee Details
2.2.2 Ganlee Major Business
2.2.3 Ganlee Oral Hypoglycemic Agents and Insulin Analogues Product and Services
2.2.4 Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Biocon
2.3.1 Biocon Details
2.3.2 Biocon Major Business
2.3.3 Biocon Oral Hypoglycemic Agents and Insulin Analogues Product and Services
2.3.4 Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 Novo Nordisk
2.4.1 Novo Nordisk Details
2.4.2 Novo Nordisk Major Business
2.4.3 Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Product and Services
2.4.4 Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 Eli Lilly
2.5.1 Eli Lilly Details
2.5.2 Eli Lilly Major Business
2.5.3 Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Product and Services
2.5.4 Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 Tonghua Dongbao
2.6.1 Tonghua Dongbao Details
2.6.2 Tonghua Dongbao Major Business
2.6.3 Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Product and Services
2.6.4 Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.7 United Laboratory
2.7.1 United Laboratory Details
2.7.2 United Laboratory Major Business
2.7.3 United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Product and Services
2.7.4 United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.8 Jiangsu Wanbang
2.8.1 Jiangsu Wanbang Details
2.8.2 Jiangsu Wanbang Major Business
2.8.3 Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Product and Services
2.8.4 Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Oral Hypoglycemic Agents and Insulin Analogues Sales by Manufacturer
3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Oral Hypoglycemic Agents and Insulin Analogues
3.4 Market Concentration Rate
3.4.1 Top 3 Oral Hypoglycemic Agents and Insulin Analogues Manufacturer Market Share
3.4.2 Top 6 Oral Hypoglycemic Agents and Insulin Analogues Manufacturer Market Share
3.5 Global Oral Hypoglycemic Agents and Insulin Analogues Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Oral Hypoglycemic Agents and Insulin Analogues Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Oral Hypoglycemic Agents and Insulin Analogues Market Size by Region
4.1.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Region (2016-2026)
4.1.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region (2016-2026)
4.2 North America Oral Hypoglycemic Agents and Insulin Analogues Revenue (2016-2026)
4.3 Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue (2016-2026)
4.4 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue (2016-2026)
4.5 South America Oral Hypoglycemic Agents and Insulin Analogues Revenue (2016-2026)
4.6 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Type (2016-2026)
5.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type (2016-2026)
5.3 Global Oral Hypoglycemic Agents and Insulin Analogues Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Application (2016-2026)
6.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application (2016-2026)
6.3 Global Oral Hypoglycemic Agents and Insulin Analogues Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2016-2026)
7.2 North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2016-2026)
7.3 North America Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country
7.3.1 North America Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Country (2016-2026)
7.3.2 North America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2016-2026)
8.2 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2016-2026)
8.3 Europe Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country
8.3.1 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Country (2016-2026)
8.3.2 Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2016-2026)
9.2 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2016-2026)
9.3 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Market Size by Region
9.3.1 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2016-2026)
10.2 South America Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2016-2026)
10.3 South America Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country
10.3.1 South America Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Country (2016-2026)
10.3.2 South America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2016-2026)
11.2 Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2016-2026)
11.3 Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country
11.3.1 Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Oral Hypoglycemic Agents and Insulin Analogues Typical Distributors
12.3 Oral Hypoglycemic Agents and Insulin Analogues Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type, (USD Million), 2021-2026
Table 2. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application, (USD Million), 2021-2026
Table 3. Sanofi-Aventis Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi-Aventis Major Business
Table 5. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Product and Services
Table 6. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Ganlee Basic Information, Manufacturing Base and Competitors
Table 8. Ganlee Major Business
Table 9. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Product and Services
Table 10. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Biocon Basic Information, Manufacturing Base and Competitors
Table 12. Biocon Major Business
Table 13. Biocon Oral Hypoglycemic Agents and Insulin Analogues Product and Services
Table 14. Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 16. Novo Nordisk Major Business
Table 17. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Product and Services
Table 18. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 20. Eli Lilly Major Business
Table 21. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Product and Services
Table 22. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Tonghua Dongbao Basic Information, Manufacturing Base and Competitors
Table 24. Tonghua Dongbao Major Business
Table 25. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Product and Services
Table 26. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. United Laboratory Basic Information, Manufacturing Base and Competitors
Table 28. United Laboratory Major Business
Table 29. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Product and Services
Table 30. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Jiangsu Wanbang Basic Information, Manufacturing Base and Competitors
Table 32. Jiangsu Wanbang Major Business
Table 33. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Product and Services
Table 34. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Manufacturer (2019-2021e) & (K MT)
Table 36. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 37. Market Position of Manufacturers in Oral Hypoglycemic Agents and Insulin Analogues, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 38. Global Oral Hypoglycemic Agents and Insulin Analogues Production Capacity by Company, (K MT): 2020 VS 2021
Table 39. Head Office and Oral Hypoglycemic Agents and Insulin Analogues Production Site of Key Manufacturer
Table 40. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2016-2021e) & (K MT)
Table 41. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2021-2026) & (K MT)
Table 42. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region (2016-2021e) & (USD Million)
Table 43. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region (2021-2026) & (USD Million)
Table 44. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2016-2021e) & (K MT)
Table 45. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2021-2026) & (K MT)
Table 46. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type (2016-2021e) & (USD Million)
Table 47. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type (2021-2026) & (USD Million)
Table 48. Global Oral Hypoglycemic Agents and Insulin Analogues Price by Type (2016-2021e) & (USD/MT)
Table 49. Global Oral Hypoglycemic Agents and Insulin Analogues Price by Type (2021-2026) & (USD/MT)
Table 50. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2016-2021e) & (K MT)
Table 51. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2021-2026) & (K MT)
Table 52. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application (2016-2021e) & (USD Million)
Table 53. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application (2021-2026) & (USD Million)
Table 54. Global Oral Hypoglycemic Agents and Insulin Analogues Price by Application (2016-2021e) & (USD/MT)
Table 55. Global Oral Hypoglycemic Agents and Insulin Analogues Price by Application (2021-2026) & (USD/MT)
Table 56. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2016-2021e) & (K MT)
Table 57. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2026) & (K MT)
Table 58. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2016-2021e) & (USD Million)
Table 59. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2021-2026) & (USD Million)
Table 60. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2016-2021e) & (K MT)
Table 61. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2021-2026) & (K MT)
Table 62. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2016-2021e) & (K MT)
Table 63. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2021-2026) & (K MT)
Table 64. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2016-2021e) & (K MT)
Table 65. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2026) & (K MT)
Table 66. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2016-2021e) & (USD Million)
Table 67. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2021-2026) & (USD Million)
Table 68. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2016-2021e) & (K MT)
Table 69. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2021-2026) & (K MT)
Table 70. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2016-2021e) & (K MT)
Table 71. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2021-2026) & (K MT)
Table 72. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2016-2021e) & (K MT)
Table 73. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2021-2026) & (K MT)
Table 74. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region (2016-2021e) & (USD Million)
Table 75. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region (2021-2026) & (USD Million)
Table 76. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2016-2021e) & (K MT)
Table 77. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2021-2026) & (K MT)
Table 78. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2016-2021e) & (K MT)
Table 79. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2021-2026) & (K MT)
Table 80. South America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2016-2021e) & (K MT)
Table 81. South America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2026) & (K MT)
Table 82. South America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2016-2021e) & (USD Million)
Table 83. South America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2021-2026) & (USD Million)
Table 84. South America Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2016-2021e) & (K MT)
Table 85. South America Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2021-2026) & (K MT)
Table 86. South America Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2016-2021e) & (K MT)
Table 87. South America Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2021-2026) & (K MT)
Table 88. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2016-2021e) & (K MT)
Table 89. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2026) & (K MT)
Table 90. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2016-2021e) & (USD Million)
Table 91. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2021-2026) & (USD Million)
Table 92. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2016-2021e) & (K MT)
Table 93. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2021-2026) & (K MT)
Table 94. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2016-2021e) & (K MT)
Table 95. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2021-2026) & (K MT)
Table 96. Direct Channel Pros & Cons
Table 97. Indirect Channel Pros & Cons
Table 98. Oral Hypoglycemic Agents and Insulin Analogues Typical Distributors
Table 99. Oral Hypoglycemic Agents and Insulin Analogues Typical Customers
List of Figures
Figure 1. Oral Hypoglycemic Agents and Insulin Analogues Picture
Figure 2. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type in 2020
Figure 3. Insulin Secretagogues
Figure 4. Alpha-glucosidase Inhibitors
Figure 5. Insulin Sensitizers
Figure 6. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application in 2020
Figure 7. Hospitals
Figure 8. Drug Store
Figure 9. Others
Figure 10. Global Oral Hypoglycemic Agents and Insulin Analogues Market Size, (USD Million) & (K MT): 2020 VS 2021 VS 2026
Figure 11. Global Oral Hypoglycemic Agents and Insulin Analogues Market Size and Forecast (2016-2026) & (USD Million)
Figure 12. United States Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 13. Canada Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 14. Mexico Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 15. Germany Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 16. France Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. United Kingdom Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. Russia Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. Italy Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. China Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. Japan Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. Korea Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. India Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Australia Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Brazil Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Egypt Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. Saudi Arabia Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. South Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Turkey Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (2016-2026) & (K MT)
Figure 32. Global Oral Hypoglycemic Agents and Insulin Analogues Production Capacity (2016-2026) & (K MT)
Figure 33. Global Oral Hypoglycemic Agents and Insulin Analogues Production Capacity by Geographic Region: 2020 VS 2021
Figure 34. Oral Hypoglycemic Agents and Insulin Analogues Market Drivers
Figure 35. Oral Hypoglycemic Agents and Insulin Analogues Market Restraints
Figure 36. Oral Hypoglycemic Agents and Insulin Analogues Market Trends
Figure 37. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Manufacturer in 2020
Figure 38. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Manufacturer in 2020
Figure 39. Oral Hypoglycemic Agents and Insulin Analogues Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 40. Top 3 Oral Hypoglycemic Agents and Insulin Analogues Manufacturer (Revenue) Market Share in 2020
Figure 41. Top 6 Oral Hypoglycemic Agents and Insulin Analogues Manufacturer (Revenue) Market Share in 2020
Figure 42. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Region (2016-2026)
Figure 43. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Region (2016-2026)
Figure 44. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue (2016-2026) & (USD Million)
Figure 45. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue (2016-2026) & (USD Million)
Figure 46. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue (2016-2026) & (USD Million)
Figure 47. South America Oral Hypoglycemic Agents and Insulin Analogues Revenue (2016-2026) & (USD Million)
Figure 48. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue (2016-2026) & (USD Million)
Figure 49. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2016-2026)
Figure 50. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Type (2016-2026)
Figure 51. Global Oral Hypoglycemic Agents and Insulin Analogues Price by Type (2016-2026) & (USD/MT)
Figure 52. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2016-2026)
Figure 53. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Application (2016-2026)
Figure 54. Global Oral Hypoglycemic Agents and Insulin Analogues Price by Application (2016-2026) & (USD/MT)
Figure 55. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Country (2016-2026)
Figure 56. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Country (2016-2026)
Figure 57. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2016-2026)
Figure 58. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2016-2026)
Figure 59. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Country (2016-2026)
Figure 60. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Country (2016-2026)
Figure 61. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2016-2026)
Figure 62. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2016-2026)
Figure 63. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Region (2016-2026)
Figure 64. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Region (2016-2026)
Figure 65. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Region (2016-2026)
Figure 66. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2016-2026)
Figure 67. South America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Country (2016-2026)
Figure 68. South America Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Country (2016-2026)
Figure 69. South America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2016-2026)
Figure 70. South America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2016-2026)
Figure 71. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Country (2016-2026)
Figure 72. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Country (2016-2026)
Figure 73. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2016-2026)
Figure 74. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2016-2026)
Figure 75. Sales Channel: Direct Channel vs Indirect Channel
Figure 76. Methodology
Figure 77. Research Process and Data Source
世界のインスリンパッチ式ポンプ市場 2021：企業別、地域別、種類・用途別 The Insulin Patch Pump market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations,…- 世界のCISインスリン市場規模・現状・予測（2021年-2027年） Insulin is a peptide hormone produced by beta cells of the pancreatic islets, which is considered to be the main anabolic hormone of the body. Russia is estimated to witness a significant growth over the next decade owing to the various subsidies provided by the local government. Market Analysis and…
- 世界の糖尿病用非インスリン療法市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Non-Insulin Therapies for Diabetes Market The global Non-Insulin Therapies for Diabetes market size is projected to reach US$ 54930 million by 2026, from US$ 30040 million in 2019, at a CAGR of 8.9% during 2021-2026. With industry-standard accuracy in analysis an…
- 世界の獣医用インスリン治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Veterinary Insulin Drugs Market The global Veterinary Insulin Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the …
- 世界の非インスリンパッチポンプ市場 2021：企業別、地域別、種類・用途別 The Non-insulin Patch Pumps market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…